High-throughput sequencing detection and ensartinib treatment of lung cancer harboring NTRK1 fusion  

作　　者：Zhengbo Song Chunwei Xu Xingxiang Pu Youcai Zhu Wenxian Wang Xingliang Li Yanqiu Gao Wenliang Zhu Yunwei He Lin Wu Li Mao Li Chen Ming Chen 

机构地区：[1]Department of Medical Oncology,Institute of Cancer and Basic Medicine,Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou,Zhejiang 310002,P.R.China [2]Department of Pathology,Fujian Cancer Hospital,Fuzhou,Fujian 350014,P.R.China [3]Department of Thoracic Oncology,Hunan Cancer Hospital,Changsha,Hunan 410013,P.R.China [4]Thoracic Disease Diagnosis and Treatment Center,Zhejiang Rongjun Hospital,Jiaxing,Zhejiang 314000,P.R.China [5]Tumor Molecular Laboratory,Zhejiang Rongjun Hospital,Jiaxing,Zhejiang 314000,P.R.China [6]HeliTec Biotechnologies,Shenzhen,Guangdong 518000,P.R.China [7]Betta Pharmaceutical,Hangzhou,Zhejiang 311100,P.R.China [8]Department of Radiotherapy,Institute of Cancer and Basic Medicine,Chinese Academy of Sciences(Zhejiang Cancer Hospital),Hangzhou,Zhejiang 310022,P.R.China

出　　处：《Cancer Communications》2021年第2期192-196,共5页癌症通讯（英文）

基　　金：This work is supported by the National Natural Science Foundation of China(No.81802276 to Z.S.).

摘　　要：Dear Editor,Although fusion events involving neurotrophic receptor tyrosine kinase 1,2,and 3 genes(NTRK1,NTRK2,and NTRK3,encoding TRKA/B/C respectively)were found in diverse tumor types,only 0.1%-0.3%of lung cancer patients harbor an NTRK(and mostly NTRK1)fusion as the primary oncogenic event[1].Such low prevalence may be partially due to the limited availability of first-line assays for detecting rare fusion events[2].Immunohistochemistry is limited by sensitivity and variable tissue background,and fluorescence in-situ hybridization falls short of elucidating functional significance such as the identity of the partner or structure of the transcript.While DNA next-generation sequencing(NGS)is suitable for mutation calling(single nucleotide variation[SNV]and insertion-or-deletion[indel]),and RNA NGS is particularly effective in detecting fusions[3],routinely performing these two assays together is labor-intensive.As a solution,we have developed a single NGS assay(PANO-Seq)for unified RNA/DNA target enrichment library preparation[4],which takes about 12 hours and $10 to prepare.

关 键 词：ROUTINE HARBOR TREATMENT 

分 类 号：R73[医药卫生—肿瘤]